Mesoblast Limited (MESO)
| Market Cap | 2.20B +27.1% |
| Revenue (ttm) | 65.38M +1,053.2% |
| Net Income | -94.37M |
| EPS | -0.07 |
| Shares Out | 1.29B |
| PE Ratio | n/a |
| Forward PE | 130.77 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 164,709 |
| Open | 16.98 |
| Previous Close | 17.43 |
| Day's Range | 16.81 - 17.11 |
| 52-Week Range | 12.66 - 21.50 |
| Beta | 0.81 |
| Analysts | Buy |
| Price Target | 35.00 (+105.88%) |
| Earnings Date | Aug 27, 2026 |
About MESO
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulc... [Read more]
Financial Performance
In fiscal year 2025, Mesoblast's revenue was $17.20 million, an increase of 191.39% compared to the previous year's $5.90 million. Losses were -$102.14 million, 16.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for MESO stock is "Buy." The 12-month stock price target is $35.0, which is an increase of 105.88% from the latest price.
News
Mesoblast Shares Jump 8.82% on ASX as Biotech Rebounds From Friday's Sharp Selloff Tied to State Street Filing
Mesoblast shares surged 8.82% on the ASX after a volatile week, recovering losses from a securities filing that unsettled investors. The company's revenue growth and clinical progress remain key focus...
Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial
Mesoblast (MESO) announced that it has completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L for chronic low back pain, CLBP, associated with the...
Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain
NEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has completed pa...
Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
Expanding indications for RYONCIL in children and adults with life-threatening inflammatory diseases Achieved target of at least 300 Patients treated in Pivotal Phase 3 trial for Chronic Low Back Pain...
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its...
Mesoblast reported Q4 Ryoncil net revenue of $36M
Last late week, Mesoblast (MESO) announced Ryoncil net revenue of $36M for the quarter and $115M for the full year ended June 30, 2026. “We are very pleased with the…
Mesoblast rises 6.2%
Mesoblast (MESO) is up 6.2%, or 96c to $16.40.
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil® (remestemcel-L-...
Mesoblast Earnings release: Q4 2026
Mesoblast released its Q4 2026 earnings on July 9, 2026, summarizing the period's financial results.
Mesoblast receives BLA filing number from FDA for rexlemestrocel-L review
Mesoblast (MESO) announced that it has received a Biologics License Application filing number from the U.S. Food and Drug Administration and has requested a modular review of its BLA for…
Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a B...
Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility
Optimized capital structure, retiring short-term maturing debt Well-funded for commercial operations and growth pipeline NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX...
Mesoblast Slides: Investor presentation
Mesoblast has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesob...
Mesoblast Earnings release: Q3 2026
Mesoblast released its Q3 2026 earnings on April 29, 2026, summarizing the period's financial results.
Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase ...
Mesoblast acquires chimeric antigen receptor platform technology
Mesoblast (MESO) “announced that it has acquired an exclusive worldwide license to a patented chimeric antigen receptor – CAR – technology platform for precision-enhanced augmentation of therapeutic m...
Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an...
Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION
Working with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification and trial awareness efforts
Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation
Mesoblast outlines commercial strategy to double net revenues as Ryoncil ® approaches US$100M net revenue milestone since launch last year
Mesoblast Transcript: R&D Day 2026
RYONCIL is driving strong revenue growth and label expansion, while late-stage programs in back pain and heart failure target multi-billion dollar markets. Next-generation MSC innovations and strategic partnerships support a robust pipeline, with financial discipline and manufacturing advances enabling sustainable growth.
Mesoblast Slides: FY 2026
Mesoblast has posted slides in relation to its FY 2026 quarterly earnings report, which was published on April 8, 2026.
Mesoblast receives IND clearance from FDA for Ryoncil trial
Mesoblast (MESO) announced that the FDA has granted investigational new drug clearance to directly proceed for a registrational clinical trial evaluating Ryoncil in Duchenne muscular dystrophy, which ...
Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy
Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients ~15,000 children are living with DMD in the U.S. NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) ...
Mesoblast reports $30.3M in Ryoncil sales in March quarter
Mesoblast (MESO) announced Ryoncil net sales were $30.3M for the quarter ended March 31. Strong sales in February and March offset holiday seasonality in January. Revenue generated during this first…